Teck Resources Ltd. Cl B Stock Falls Thursday, Underperforms Market
Dow Jones2026/10/08 20:35This article was automatically generated by MarketWatch using technology from Automated Insights. Shares of Teck Resources Ltd. Cl B TECK.B shed 1.24% to C$92.10 Thursday, in what proved to be an otherwise all-around positive trading session for the Canadian market, with the S&P/TSX Composite Index rising 0.30% to 35,145.38. Teck Resources Ltd. Cl B closed 7.8% short of its 52-week high of C$99.91, which the company achieved on September 8th. Trading volume of 793,595 shares remained below its 50-day average volume of 1.2 M. Data source: Dow Jones Market Data, FactSet. Data compiled October 8, 2026. This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal. (END) Dow Jones Newswires October 08, 2026 16:35 ET (20:35 GMT)
This article was automatically generated by MarketWatch using technology from Automated Insights.
Shares of Teck Resources Ltd. Cl B TECK.B shed 1.24% to C$92.10 Thursday, in what proved to be an otherwise all-around positive trading session for the Canadian market, with the S&P/TSX Composite Index rising 0.30% to 35,145.38.
Teck Resources Ltd. Cl B closed 7.8% short of its 52-week high of C$99.91, which the company achieved on September 8th.
Trading volume of 793,595 shares remained below its 50-day average volume of 1.2 M.
Data source: Dow Jones Market Data, FactSet. Data compiled October 8, 2026.
This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.
(END) Dow Jones Newswires
October 08, 2026 16:35 ET (20:35 GMT)
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
London Gold and Silver Vault Data for September 2026
Bristol-Myers Squibb (BMY.US) rises in pre-market trading! Two experimental drugs report positive results in Phase 3 clinical trials, diversifying and accelerating the pipeline
Bristol Myers Squibb's two experimental drugs, used to treat a rare endocrine cancer and a deadly lung disease, have achieved success in Phase III clinical trials, injecting momentum into the pharmaceutical company’s new product pipeline.
Crypto prices
More
